PIK3CD and B-cell chronic lymphocytic leukemia: Inhibition of p110δ, both pharmacologically and via siRNA knockdown, decreased ADCC and ADP in CLL-derived NLCs (107), suggesting that this catalytic isoform is essential for CLL-derived NLC as well as macrophage response to therapeutic antibodies.